Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Factor VIII (FVIII)
DRUG
3 trials
Sponsors
Hoffmann-La Roche
, Dhaka Medical College
, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions
Hemophilia A
TTP - Thrombotic Thrombocytopenic Purpura
Phase 2
Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Not yet recruiting
NCT06938659
Dhaka Medical College
Hemophilia A
Start: 2025-06-01
End: 2026-07-31
Target: 20
Updated: 2025-04-22
Phase 3
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
Completed
NCT02847637
Hoffmann-La Roche
Hemophilia A
Start: 2016-09-27
End: 2022-05-12
Updated: 2022-11-16
Unknown Phase
MICROVASCULAR DAMAGE IN THROMBOTIC THROMBOCYTOPENIC PURPURA
Active, not recruiting
NCT07615244
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
TTP - Thrombotic Thrombocytopenic Purpura
Start: 2026-02-28
End: 2032-01-31
Target: 79
Updated: 2026-06-09
Related Papers
Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab
Blood
2025-11-03
Pain‐Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies
Haemophilia
2024-12-18
2 citations
Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.
2024-03-01
2 citations
Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
Haemophilia
2023-06-22
8 citations
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
Blood Advances
2022-08-08
41 citations
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
Haemophilia
2022-07-29
32 citations
Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)
Blood
2021-11-05
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Blood
2020-12-19
270 citations
Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)
Blood
2020-11-04
4 citations
Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3
Blood
2019-11-13
6 citations
Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Blood
2019-11-13
5 citations
Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study
Hämostaseologie
2019-02-01
2 citations
Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study
Hämostaseologie
2019-02-01
1 citations
Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies
Blood
2018-11-29
58 citations
Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)
Blood
2018-11-29
11 citations
Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies
Blood
2018-11-29
7 citations
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
New England Journal of Medicine
2018-08-29
707 citations
Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)
Blood
2017-12-07
18 citations